IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major investor relations events in February 2025. The company will be featured at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11th at 1:20 PM ET, where President and CEO Yujiro S. Hata will participate in a fireside chat hosted by Matthew Biegler.
Additionally, IDEAYA will join Citi's 2025 Virtual Oncology Leadership Summit on February 19th at 12:00 PM ET, featuring another fireside chat with CEO Hata, hosted by Yigal D. Nochomovitz. Live audio webcasts of these events will be available on the company's investor relations website, with recordings accessible for 30 days after the events.
IDEAYA Biosciences (NASDAQ: IDYA), un'azienda di oncologia specializzata nella medicina di precisione, ha annunciato la sua partecipazione a due importanti eventi di relazioni con gli investitori a febbraio 2025. L'azienda sarà presente al 35° Convegno Annuale sulle Scienze della Vita di Oppenheimer l'11 febbraio alle 13:20 ET, dove il Presidente e CEO Yujiro S. Hata parteciperà a una chiacchierata informale moderata da Matthew Biegler.
Inoltre, IDEAYA parteciperà al Vertice Virtuale di Leadership Oncologica 2025 di Citi il 19 febbraio alle 12:00 ET, con un'altra chiacchierata informale con il CEO Hata, moderata da Yigal D. Nochomovitz. I webcast audio live di questi eventi saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda, con registrazioni accessibili per 30 giorni dopo gli eventi.
IDEAYA Biosciences (NASDAQ: IDYA), una empresa de oncología de medicina de precisión, ha anunciado su participación en dos importantes eventos de relaciones con inversionistas en febrero de 2025. La empresa estará presente en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer el 11 de febrero a la 1:20 PM ET, donde el Presidente y CEO Yujiro S. Hata participará en una charla en formato de fogata moderada por Matthew Biegler.
Además, IDEAYA se unirá al Encuentro Virtual de Liderazgo Oncológico 2025 de Citi el 19 de febrero a las 12:00 PM ET, con otra charla al estilo de fogata con el CEO Hata, moderada por Yigal D. Nochomovitz. Las transmisiones en vivo de audio de estos eventos estarán disponibles en el sitio web de relaciones con inversionistas de la empresa, con grabaciones accesibles durante 30 días después de los eventos.
IDEAYA Biosciences (NASDAQ: IDYA)는 정밀 의학 전문 온코로지 회사로, 2025년 2월에 진행되는 두 개의 주요 투자자 관계 행사에 참여한다고 발표했습니다. 이 회사는 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 2월 11일 오후 1시 20분(ET)에 참가하며, 여기서 사장 겸 CEO인 유지로 S. 하타가 매튜 비글러가 주최하는 대담에 참여할 것입니다.
또한 IDEAYA는 씨티의 2025년 가상 종양학 리더십 서밋에 2월 19일 오후 12시(ET)에 참가하며, 여기서 CEO 하타와의 또 다른 대담이 이루어질 예정이며, 이 대담은 이갈 D. 노호모비츠가 주최합니다. 이 행사들의 생중계 오디오 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공되며, 행사가 끝난 후 30일 동안 녹화에 접근할 수 있습니다.
IDEAYA Biosciences (NASDAQ: IDYA), une entreprise d'oncologie en médecine de précision, a annoncé sa participation à deux grands événements de relations investisseurs en février 2025. L'entreprise sera présente à la 35e Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer le 11 février à 13h20 ET, où le Président et CEO Yujiro S. Hata participera à une discussion informelle animée par Matthew Biegler.
De plus, IDEAYA rejoindra le Sommet Virtuel de Leadership Oncologique 2025 de Citi le 19 février à 12h00 ET, avec une autre discussion informelle avec le CEO Hata, animée par Yigal D. Nochomovitz. Les webcasts audio en direct de ces événements seront disponibles sur le site des relations investisseurs de l'entreprise, avec des enregistrements accessibles pendant 30 jours après les événements.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen für Präzisionsmedizin in der Onkologie, hat seine Teilnahme an zwei wichtigen Investor Relations-Veranstaltungen im Februar 2025 bekannt gegeben. Das Unternehmen wird am 35. jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer am 11. Februar um 13:20 Uhr ET teilnehmen, wo Präsident und CEO Yujiro S. Hata in einem von Matthew Biegler moderierten Kamin-Gespräch dabei sein wird.
Darüber hinaus wird IDEAYA am Virtuellen Onkologie-Leaders-Gipfel 2025 von Citi am 19. Februar um 12:00 Uhr ET teilnehmen, ebenfalls mit einem weiteren Kamin-Gespräch mit CEO Hata, moderiert von Yigal D. Nochomovitz. Live-Audio-Webcasts dieser Veranstaltungen sind auf der Investor Relations-Website des Unternehmens verfügbar, die Aufzeichnungen sind für 30 Tage nach den Veranstaltungen abrufbar.
- None.
- None.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Tuesday, February 11th, 2025 at 1:20 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Matthew Biegler, Executive Director and Senior Analyst
Citi's 2025 Virtual Oncology Leadership Summit
Wednesday, February 19th, 2025 at 12:00 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
A live audio webcast of the conference event, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-february-2025-investor-relations-events-302360092.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) presenting at the Oppenheimer Healthcare Conference in 2025?
What investor conferences is IDYA attending in February 2025?
How long will IDYA's February 2025 conference webcasts be available for replay?
Where can investors access IDYA's February 2025 conference presentations?
